Amos Tsai

Amos Tsai currently serves as Senior Director at Samsung Biologics, following a role as Senior Director at Autolus Ltd., where responsibilities included overseeing late-phase process and product development for autologous CAR-T therapies. Prior experience includes positions at Johnson & Johnson as Principal Scientist in Drug Product Development and Technical Operations, where Tsai led initiatives in CAR-T technologies and manufacturing processes. Career beginnings were at Amgen as Principal Scientist in Global Process Engineering, and at Human Genome Sciences as Principal Scientist in Process Development & Manufacturing Sciences. Tsai's early research as Staff Scientist at the National Institute of Standards and Technology focused on protein dynamics and stability. Tsai earned a Ph.D. in Chemical Engineering from The Johns Hopkins University.